SciClone Signs MedCo To Fill CV Warchest In China
This article was originally published in PharmAsia News
Executive Summary
It’s a Santa Surprise for SciClone with two cardiovascular agent additions from The Medicines Co. after the termination of a Sanofi promotion agreement a year ago. China’s lengthy and unpredictable regulatory process, however, could cast a shadow over the cheerful prospects.